Indian Journal of Urology
ORIGINAL ARTICLE
Year
: 2014  |  Volume : 30  |  Issue : 1  |  Page : 33--37

External validation of the modified Glasgow prognostic score for renal cancer


Caroline G Tai1, Timothy V Johnson1, Ammara Abbasi1, Lindsey Herrell1, Wayne B Harris1, Omer Kucuk2, Daniel J Canter1, Kenneth Ogan1, John G Pattaras1, Peter T Nieh1, Viraj A Master1 
1 Department of Urology, Emory University, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
2 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Correspondence Address:
Viraj A Master
Department of Urology, 1365 Clifton Road NE, Atlanta, GA 30322, 404 217 6419
USA

Purpose: The modified Glasgow prognostic Score (mGPS) incorporates C-reactive protein and albumin as a clinically useful marker of tumor behavior. The ability of the mGPS to predict metastasis in localized renal cell carcinoma (RCC) remains unknown in an external validation cohort. Patients and Methods: Patients with clinically localized clear cell RCC were followed for 1 year post-operatively. Metastases were identified radiologically. Patients were categorized by mGPS score as low-risk (mGPS = 0 points), intermediate-risk (mGPS = 1 point) and high-risk (mGPS = 2 points). Univariate, Kaplan-Meier and multivariate Cox regression analyses examined Recurrence -free survival (RFS) across patient and disease characteristics. Results: Of the 129 patients in this study, 23.3% developed metastases. Of low, intermediate and high risk patients, 10.1%, 38.9% and 89.9% recurred during the study. After accounting for various patient and tumor characteristics in multivariate analysis including stage and grade, only mGPS was significantly associated with RFS. Compared with low-risk patients, intermediate- and high-risk patients experienced a 4-fold (hazard ratios [HR]: 4.035, 95% confidence interval [CI]: 1.312-12.415, P = 0.015) and 7-fold (HR: 7.012, 95% CI: 2.126-23.123 P < 0.001) risk of metastasis, respectively. Conclusions: mGPS is a robust predictor of metastasis following potentially curative nephrectomy for localized RCC. Clinicians may consider mGPS as an adjunct to identify high-risk patients for possible enrollment into clinical trials or for patient counseling


How to cite this article:
Tai CG, Johnson TV, Abbasi A, Herrell L, Harris WB, Kucuk O, Canter DJ, Ogan K, Pattaras JG, Nieh PT, Master VA. External validation of the modified Glasgow prognostic score for renal cancer.Indian J Urol 2014;30:33-37


How to cite this URL:
Tai CG, Johnson TV, Abbasi A, Herrell L, Harris WB, Kucuk O, Canter DJ, Ogan K, Pattaras JG, Nieh PT, Master VA. External validation of the modified Glasgow prognostic score for renal cancer. Indian J Urol [serial online] 2014 [cited 2021 Sep 21 ];30:33-37
Available from: https://www.indianjurol.com/article.asp?issn=0970-1591;year=2014;volume=30;issue=1;spage=33;epage=37;aulast=Tai;type=0